Netherlands vs Romania: Share of the population living with HIV receiving antiretroviral therapy
Netherlands
88.6%
in 2023
Romania
89.2%
in 2024
Netherlands rank
22nd
Romania rank
21st
Share of the population living with HIV receiving antiretroviral therapy over time
- Netherlands
- Romania
How they compare
Romania currently reports 89.2% against 88.6% in Netherlands, a difference of 0.6%.
The two have swapped places 1 time across 34 shared years of data; in 1990 it was Romania ahead.
Netherlands ranks 22nd and Romania ranks 21st of 149 countries.
Netherlands has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Netherlands | Romania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 15.1% | 5.6% | 9.6% | Netherlands |
| 2000s | 53.4% | 44.6% | 8.8% | Netherlands |
| 2010s | 77.2% | 63.4% | 13.8% | Netherlands |
| 2020s | 87.8% | 78.7% | 9.1% | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Netherlands or Romania?
- Romania, at 89.2% against 88.6% in Netherlands as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Netherlands and Romania?
- 0.6%, with Romania ahead.
- How many years of comparable data are there for Netherlands and Romania?
- 34 years are reported by both, from 1990 to 2023.
- How do Netherlands and Romania rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Netherlands ranks 22nd and Romania ranks 21st of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.